Cover
Cover | Sep. 02, 2022 |
Cover [Abstract] | |
Entity Registrant Name | Yubo International Biotech Limited |
Entity Central Index Key | 0000895464 |
Document Type | 8-K/A |
Amendment Flag | true |
Entity Emerging Growth Company | false |
Document Period End Date | Sep. 02, 2022 |
Entity File Number | 0-21320 |
Entity Incorporation State Country Code | NY |
Entity Tax Identification Number | 11-3074326 |
Entity Address Address Line 1 | Room 105 |
Entity Address Address Line 2 | Building 5 |
Entity Address Address Line 3 | 31 Xishiku Avenue |
Entity Address City Or Town | Xicheng District |
Entity Address Region | Beijing |
Entity Address Country | CN |
Entity Address Postal Zip Code | 100034 |
City Area Code | 040 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Local Phone Number | 0677-6010 |
Amendment Description | On September 9, 2022, Yubo International Biotech Limited, a New York Corporation (the “Company”), filed a Current Report on Form 8-K (the “Original 8-K”) with the U.S. Securities and Exchange Commission (the “SEC”) to report under “Item 1.01 Entry into a Material Definitive Agreement”, the entry into a Securities Purchase Agreement with World Precision Medicine Technology Limited. This Current Report on Form 8-K/A (this “8-K/A”) is being filed as an amendment to the Original 8-K for the sole purposes of amending the use of proceeds from the sale of the Shares under the Securities Purchase Agreement and furnishing the Amendment to Securities Purchase Agreement as an exhibit. Except as otherwise specified in this 8-K/A, the Original 8-K shall remain unchanged in all material respects. Capitalized terms used but not otherwise defined herein have the respective meanings ascribed to them in the Original 8-K. |